Word: inhibitor
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Chemistry Of The Brain" [THE FUTURE OF DRUGS, Jan. 15], on the latest medical developments for many serious diseases, contained inaccurate information about duloxetine, a compound being developed by Eli Lilly & Co. for the treatment of depression. Duloxetine is not among the class of antidepressants called selective serotonin reuptake inhibitors. In fact, duloxetine is a powerful and balanced reuptake inhibitor of both serotonin and norepinephrine, one of the other main neurotransmitters involved in depression. This is a much different approach offering a potentially more effective and better-tolerated treatment. JOHN HAYES, M.D. Executive Director and Leader Duloxetine Antidepressant Team...
...present, the likelihood that this particular vaccine or this particular secretase inhibitor will end up in the therapeutic arsenal has to be considered slim. Of all the compounds his team brings forward, says Molinoff, only 10% to 15% manage to pass the rigorous series of tests that lead to approval by the U.S. Food and Drug Administration. And even when they do, Harvard University neurologist Dr. Kenneth Kosik emphasizes, precious few new drugs prove to be anything close to magic bullets. Indeed, Kosik, along with many others, thinks it is quite likely that controlling Alzheimer's disease will require more...
...comes from studies of a vaccine against beta amyloid that Schenk and his co-workers at Elan have developed. In 1999 they administered their vaccine to mice whose brains were filled with plaques. A short time later, the plaques shrank. Currently the Elan vaccine, like the Bristol-Myers' secretase inhibitor, is in early-phase clinical trials, in which the primary objective is to test for safety as opposed to effectiveness...
...most recent results, 30% showed no sign of the chromosomal damage that marks the disease and appeared to have been cured. "This drug is amazing," says Richard Stone, an oncologist at the Dana-Farber Cancer Institute who has been testing Glivec (also known as an STI, for signal transduction inhibitor). "Even patients who are near death, at the end stage of this disease, are going into remission...
Prozac is another drug that targets a particular neurotransmitter, plugging up brain chemicals that absorb the mood elevator called serotonin. Competing ssris (selective serotonin reuptake inhibitors), as they're called, include Lilly's duloxetine and Solvay Pharmaceuticals' fluvoxamine. Both drugs affect the same biochemical pathways, only with greater precision and fewer side effects. But better ssris aren't the only new approach. Sanofi-Synthelabo is looking into the potential of a so-called mao (monoamine oxidase) inhibitor called befloxatone. Monoamine oxidase is another serotonin-disrupting enzyme, so anything that inhibits it should make more of the mood-elevating chemical available...